A meningioma is the second most common primary intracranial tumor of the central nervous system. One critical obstacle in meningioma research and preclinical development of novel therapeutic agents is a relative lack of suitable preclinical in vitro and in vivo model systems. In the current study, we assessed the proliferative characteristics of patient derived five primary meningioma cancer cell lines (WHO grade I and II) from brain tumor lesions. All of the meningioma cell lines showed homogenous expression of meningioma marker, VIMENTIN. The GTG-banding analysis determined the existence of different patterns of chromosomal abnormalities in representative cancer cell lines. The almost of the meningioma cell lines showed homogeneously spindle shaped cells, except for M160425 which have two prominent cell morphologies, spindle and round. Population-doubling (PD) was measured for every passage. The M160425 cell line had significantly longer PD time (39.8 ± 0.9 h, P<0.05) than the other meningioma cell lines. Consistent with the PD time, we confirmed that mRNA expression of Ki67, the conventional proliferation marker, was significantly lower in M160425 cell line compared to the other cell lines. The correlation between the PD time and the abundance of Ki67 in the meningioma derived cell lines was negative, indicating higher Ki67 abundance and a shorter PD time. The patient derived meningioma cancer cell lines established in this study might contribute to understanding cancer biology and help the success in the clinic by explaining the slightly different clinical behavior among the patients.